Canopy Growth Restates Two Years of Results as Warrant Classification Error Triggers Insider Trading Freeze

Canopy Growth restates fiscal 2024-2025 results over a warrant classification error, triggering a 5.6% stock drop and a trading ban on top executives. Cash position unchanged.

A technical accounting error has forced Canopy Growth to restate its financial statements for fiscal 2024 and 2025, sending shares lower and prompting a temporary trading ban on the company’s top executives. The Canadian cannabis producer disclosed the misstep on May 19, 2026, during preparations for its fiscal 2026 annual report, triggering a swift regulatory response.

The issue stems from the incorrect classification of certain share purchase warrants — a non-cash adjustment that leaves revenue, gross margins, operating profit and cash flow untouched. Management stressed that the correction does not affect the company’s cash position, which remains at roughly $270 million, nor its day-to-day operations. Still, investors took a cautious view. On the Toronto Stock Exchange, the stock fell about 5.6% to close at C$1.34, while the U.S.-listed shares dipped approximately 2% to just under $0.96.

In response to the delayed filings, Canopy Growth applied for a Management Cease Trade Order. If approved, the order would bar Chief Executive Officer David Klein and Chief Financial Officer Judy Hong from trading the company’s shares until the corrected documents are submitted. Regular shareholders face no restrictions and can continue buying and selling freely.

The restated accounts will be released alongside fiscal 2026 results on June 15, marking a key date for the company’s credibility. Analysts, who rate the stock a consensus “Hold,” expect the fourth-quarter loss per share to narrow to $0.11 from $0.36 a year earlier. The updated filings will show whether the warrant reclassification has any lasting impact on the balance-sheet structure.

Meanwhile, short sellers have been paring their bets. The short interest in Canopy Growth has edged lower to 6.33% of the float, a decline of roughly five percentage points — suggesting some bearish investors see the worst as priced in. The market capitalization stands at around $399 million.

Beyond the accounting distraction, the company continues to push its operational agenda. A newly announced partnership with Illinois CancerCare aims to widen patient access to medical cannabis, adding a growth vector as the June reporting deadline approaches. The combination of a clean earnings release and progress on the medical front could determine whether this stock regains its footing or remains trapped in the correction cycle.